Fox Run Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Fox Run Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,352	Closed	-$260K	–	954
2022 Q3	$260K	Buy	+10,352	New	+$287K	0.1%	401
2020 Q3	–	Sell	-1,452	Closed	-$227K	–	352
2020 Q2	$227K	Sell	1,452 -308	-18%	-$46.8K	0.3%	181
2020 Q1	$254K	Buy	1,760 +507	+40%	+$97.9K	0.6%	47
2019 Q4	$256K	Buy	+1,253	New	+$229K	0.21%	251

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Fox Run Management's RETA Position: Q4 2022 in Review

Fox Run Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 10,352 shares — an estimated $260K sold.

Fox Run Management first reported a position in RETA in Q4 2019 and held it in 4 quarters. The position peaked at $260K in Q3 2022. 168 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

Fox Run Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Fox Run Management sold 10,352 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $260K.
Fox Run Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 4 quarters.
Fox Run Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $260K in Q3 2022.
168 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on Fox Run Management's 13F filing for Q4 2022, filed 7 Feb 2023.